Quansys Q-Plex technology
December 2019—Quansys Biosciences (Logan, Utah) announced that its Q-Plex technology has been selected as a featured innovation at the Geneva Health Forum in Switzerland, March 24–26, 2020.
Webinars and Sponsored Roundtables — Register Now
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
DiaSorin VZV swab test gets CE mark
December 2019—DiaSorin Molecular received the CE mark for its Simplexa VZV Swab Direct assay. The molecular diagnostic test enables the direct detection of varicella-zoster virus DNA from cutaneous and mucocutaneous swab specimens.
Menarini launches MSBiosuite
December 2019—Menarini Silicon Biosystems launched MSBiosuite, a cloud-based solution that automates next-generation-sequencing data analysis for liquid biopsy and formalin-fixed, paraffin-embedded workflows. The solution, developed in partnership with BlueBee, provides NGS data processing, analysis, interpretation, and reporting for users of Menarini NGS library preparation kits. A clinical interpretation report is available optionally with the Ampli1 and DEPArray OncoSeek pipelines.
Nova Biomedical introduces electrolyte analyzer
December 2019—Nova Biomedical announced the release of its Stat Profile Prime ES Comp Plus. The analyzer offers a complete electrolyte profile, including ionized magnesium, and optional serial batch testing on whole blood, serum, or plasma.
CellaVision buys RAL Diagnostics
December 2019—On Oct. 1, CellaVision completed the acquisition of RAL Diagnostics (Martillac, France). RAL develops and sells products for sample preparation in hematology, microbiology, cytology, and pathology.
Direct HbA1c testing in whole blood
December 2019—The Randox RX series provides laboratories with the capabilities of onboard HbA1c testing in whole blood on three fully automated RX analyzers—RX Modena, RX Imola, and RX Daytona+ —to accommodate rapid and reliable measurement of HbA1c in different laboratory settings.
T2Resistance Panel available as RUO test
December 2019—T2 Biosystems announced that its T2Resistance Panel is available as a research use only test in the United States. The panel is expected to receive the CE mark by the end of 2019.
Hematogenix BCMA flow cytometry, IHC assays
December 2019—Hematogenix announced the availability of the assessment of B-cell maturation antigen by flow cytometry and immunohistochemistry at its facilities in China, Asia, Europe, and the United States.
High-yield liquid biopsy sample prep platform
December 2019—nRichDX introduced its Revolution System, a high-yield sample prep platform designed to increase liquid biopsy–based test sensitivity by delivering more target input for molecular assays. The target yield increase is accomplished by combining the ability to process a range of sample volumes (3–50 mL) with recovery rates of 70–90 percent.
Capmatinib designated as breakthrough therapy
December 2019—The FDA granted breakthrough therapy designation to Novartis’ capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.